Premature and early menopause and neuroimaging biomarkers of neurodegenerative diseases: a systematic review
Frontiers in Dementia · 12.08.2026 · 5
DOI: 10.3389/frdem.2026.1912295 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Dementia, online erschienen am 12.08.2026. Verfasst von Emily Gallmetzer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN, United States. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Background
Premature and early menopause involve ovarian hormone deprivation, which may contribute to later-life vulnerability to cognitive decline and neurodegenerative diseases. Multimodal neuroimaging biomarkers provide a means of detecting structural, microstructural, functional, and molecular brain changes before clinical symptoms emerge.
Methods
Following PRISMA guidelines, we conducted a systematic search of PubMed. Study quality was assessed using the Newcastle–Ottawa Scale.
Results
Neuroimaging modalities included in vivo structural magnetic resonance imaging (MRI) ( n = 16), functional MRI ( n = 2), diffusion tensor imaging ( n = 4), and positron emission tomography ( n = 3). Women with premature or early menopause showed regionally specific structural and microstructural brain abnormalities, including lower gray-matter volume or cortical thickness in medial temporal, frontal, and basal forebrain regions; white-matter microstructural abnormalities in the anterior corona radiata, corpus callosum, and fronto-occipital tracts; and reduced posterior hippocampal activation during memory encoding. In one study, earlier age at menopause was associated with higher amyloid- β (Aβ) burden in women who underwent premenopausal bilateral oophorectomy (PBO), and elevated tau deposition was reported predominantly among women with higher Aβ levels.
Conclusion
Converging multimodal neuroimaging evidence suggests that premature and early menopause may be associated with Alzheimer’s disease-relevant brain changes. However, findings remain heterogeneous, and longitudinal studies are needed to clarify the temporal relationships between ovarian hormone deprivation and neurodegeneration, and to determine the clinical implication of these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, MN, United States.
- Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
- Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
- Women's Health Research Center, Mayo Clinic, Rochester, MN, United States.
- Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
- Department of Neurology, Mayo Clinic, Rochester, MN, United States.
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
Zitieren
APA
Gallmetzer, E., Mak, E., Kara, F., Zeydan, B., Kapoor, E., Shufelt, C. L., Rocca, W. A., & Kantarci, K. (2026). Premature and early menopause and neuroimaging biomarkers of neurodegenerative diseases: a systematic review. Frontiers in Dementia, 5. https://doi.org/10.3389/frdem.2026.1912295
Vancouver
Gallmetzer E, Mak E, Kara F, Zeydan B, Kapoor E, Shufelt CL, et al. Premature and early menopause and neuroimaging biomarkers of neurodegenerative diseases: a systematic review. Frontiers in Dementia. 2026;5. doi:10.3389/frdem.2026.1912295
BibTeX
@article{Gallmetzer2026,
author = {Gallmetzer, Emily and Mak, Elijah and Kara, Firat and Zeydan, Burcu and Kapoor, Ekta and Shufelt, Chrisandra L and Rocca, Walter A and Kantarci, Kejal},
title = {Premature and early menopause and neuroimaging biomarkers of neurodegenerative diseases: a systematic review},
journal = {Frontiers in Dementia},
year = {2026},
volume = {5},
doi = {10.3389/frdem.2026.1912295}
}
EUVIMED